by admin
Share
This past week, we reached a milestone that is nothing short of extraordinary. Our very first patients received the Ocumetics Accommodating Intraocular Lens. Just one week later, they are recovering well—and importantly, no complications have been observed.
I cannot overstate how meaningful this moment is. For years, we have poured our hearts, energy, and belief into making the Ocumetics Lens a reality. To now see it safely implanted and beginning to change lives is remarkable. These are the moments we dreamed of.
The early signs are encouraging and give us confidence as we move forward with the next surgical day and complete the first group of patients. The real test lies ahead, as healing continues and vision outcomes begin to emerge.
This achievement is proof that bold ideas, relentless effort, and true teamwork can change the world. And make no mistake—we are changing the world.
Thank you for believing. Thank you for persevering. And thank you for standing shoulder to shoulder with us on this journey. Together, we are making history.
With pride and gratitude,
Dean Burns
President, CEO and Director
Ocumetics Technology
Key Highlights Early First-in-Human clinical results have drawn the attention of industry leaders and several of the largest vision care technology companies in the world. Ocumetics will leverage the conference to further engage with global strategic partners to accelerate development and commercialization efforts. Calgary, Canada – TheNewswire – April 1, 2026 – Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSV:V OTC) (OTCQB: OTCFF) (FRA:
Key Highlights Breakthrough Accommodating Interocular Lens Design: The enhanced lens design introduces several novel concepts that are expected to improve substantially upon the consistency, durability, and manufacturability of the lens. Enhanced Performance with Greater Reliability: This next-generation technology is anticipated to deliver natural optical responsiveness and improved mechanical stability, supporting excellent vision across its full
Calgary, Alberta – February 10, 2026 – TheNewswire – Ocumetics Technology Corp. (“Ocumetics” or the “Corporation”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) is pleased to announce that the Corporation has entered into a forbearance agreement with the holders of secured convertible debentures (the “Debentures”) that were issued by the Corporation in May and June 2024 (see press release
